Login to Your Account

Making music with MIT tech

Flu fighters: $46.7M rocks Visterra, pieces of APRIL key in nephropathy bid

By Randy Osborne
Staff Writer

Thursday, October 5, 2017

"Nobody has done this before," Visterra Inc. CEO Brian Pereira told BioWorld, talking about the company's approach in immunoglobulin A (IgA) nephropathy, an effort that is part of what fueled his company's just-finished $46.7 million series C financing. 

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription